Bristol-myers Squibb Compnay

Conopco, Inc.

Genentech, Inc.

Other

E. R. Squibb Sons, Inc.

Syngenta Corporation

Amphora Discovery Corporation

John Kenneth Dickson, Jr

Scott A Biller

R Michael Lawrence

Ian Stuart Cloudsdale

Bijan Steven Harichian

Richard B Sulsky

David R Magnin

Carl Nicholas Hodge

Van Au

Timur Gungor

Ke Chen

Jose Mendoza

James R Corte

Ashvinikumar V Gavai

Wu Yang

Richard A Partyka

Yufeng Wang

Jacques Y Roberge

Teanoosh Moaddel

Lin Yang

Russell Colin Viner

John Steven Bajor

Kevin P Williams

John Benjamin Taylor

Shuji Hachisu

Janice Black

David P Rotella

Emma Briggs

Richard E Gregg

Jianming Lee

Roy J Vaz

Alaric James Avery

Ian Henry Aspinall

John R Wetterau, Ii

John E Lawson

Henry M Holava

Daru Young Sharp

Jeffery Steven Wailes

Simon Hardy

The invention is directed to a cosmetic composition and the precursor thereof. The composition has solid agent and liquid agent, both of which are cosmetic benefit ingredients. The solubility of solid agents in liquid agents in the inventive compositions is enhanced in the presence of a tricyclodecane amide.

Cosmetic compositions with tricyclodecane amides

The present invention relates to a compound of formula (I): wherein the substituents are as defined herein, and wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are thought to be suitable for use as herbicides. The invention therefore also relates to a method of controlling weeds, especially grassy monocotyledonous weeds, in crops of useful plants, comprising applying a compound of formula (I), or a herbicidal composition comprising such a compound, to the plants or to the locus thereof. 

Herbicidally active 2-(substituted-phenyl)-cyclopentane-1,3-dione compounds and derivatives thereof

A personal care composition is provided having a highly volatile fragrance which incorporates alpha pinene, beta pinene, hexyl acetate, limonene, (+)-citronellal, dihydromyrcenol, alpha citronellol, beta citronellol, genaniol, lilial or combinations thereof in conjunction with tricyclodecane amide. The tricyclodecane amide functions to prevent fast volatilization of the highly volatile fragrance components when the personal care composition is applied to skin or hair of the human body.

Prolonged delivery of certain fragrance components from personal care compositions

A personal care photoprotective composition is provided having a UV-A and UV-B sunscreen in conjunction with a tricyclodecane amide. The tricyclodecane amide functions to boost UV-A, UV-B and SPF performance when the personal care composition is applied to skin or hair of the human body.

Personal care photoprotective compositions with tricyclodecane amides

2-Amido-4-substituted-aryl-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.

2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof

Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.

Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof

2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof

The present invention relates to modulators of the calcium sensing receptor having the formula I 

Thiazolidine compounds as calcium sensing receptor modulators

The present invention relates to modulators of the calcium sensing receptor having the formula I wherein

2-substituted cyclic amines as calcium sensing receptor modulators

.alpha.-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2 is OR.sup.5 or R.sup.5a ; R.sup.3 and R.sup.5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R.sup.5a is H, alkyl, arylalkyl or aryl; R4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R.sup.1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.

.alpha.-phosphonosulfonate squalene synthetase inhibitors

Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.

Nucleic acids encoding microsomal trigyceride transfer protein

.alpha.-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2 is OR.sup.5 or R.sup.5a ; R.sup.3 and R.sup.5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R.sup.5a is H, alkyl, arylalkyl or aryl; R.sup.4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R.sup.1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.

.alpha.-phosphonosulfonate squalene synthetase inhibitors and method

Methods of using .alpha.-phosphonosulfonate squalene synthetase

Hydroxyphosphinyl phosphonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2, R.sup.3 and R.sup.4 are independently H, alkyl, metal ion or a prodrug ester; and R.sup.1 is a lipophilic group which contains at least 6 carbons and is alkyl, alkenyl, alkynyl, mixed alkenylalkynyl, a hetero-containing moiety as defined herein, or a phenylalkyl or phenylalkenyl group including those containing a biphenyl group.

Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and method

Growing community of inventors

Apex, NC, United States of America

John Kenneth Dickson, Jr